临床猪肾异种移植:我们离应用还有多远?
终末期肾病患者面临供肾短缺,等待中位时间3.9年,约35%在等待期间死亡或被移除等待名单。基因工程猪肾通过删除猪异种抗原和插入人保护性转基因,在非人灵长类中联合抗CD40单抗可获数月无排斥存活,预计2年内开展临床试验。
要点
- 终末期肾病患者等待尸体供肾中位3.9年,约35%在等待中死亡或被移除名单。
- 基因工程猪最多有9项基因操作,非人灵长类中猪肾存活数月且无排斥特征。
- 抗CD40单抗阻断CD40/CD154共刺激通路可抑制适应性免疫反应。
核心结论
- 基因工程猪肾异种移植有望解决供肾短缺,在非人灵长类中已实现数月无排斥存活,预计2年内开展临床试验。
研究设计与样本
- 原文为综述,未报告系统检索范围与样本量,汇总了基因工程猪肾异种移植在非人灵长类中的实验证据及临床转化前景。
主要发现
- 终末期肾病患者等待尸体供肾中位时间为3.9年,约35%的移植候选者在等待期间死亡或被移除等待名单。
- B型或O型血患者可能经历显著更长的等待期。
- 非人灵长类中给予抗CD40单抗等阻断CD40/CD154共刺激通路的新药,猪肾移植物存活数月且无排斥特征,实验因感染并发症终止。
- 在缺乏固有和适应性免疫应答时,移植猪肾通常显示良好的功能。
- 目前已可获得最多9项基因操作的猪。
关键数值与推荐
- 原文未报告具体的排斥诊断标准、免疫抑制方案剂量或功能阈值。
临床怎么用
- 对于预期寿命短于等待尸体供肾时间的特定患者,伦理上可考虑提供猪肾移植。
- 未来猪可能进一步基因工程化以控制适应性免疫应答,从而显著减少或消除外源性免疫抑制治疗。
局限性
- 非人灵长类实验因感染并发症终止,未报告长期存活数据。
- 临床试验尚未开展,安全性和有效性需进一步验证。
- 原文未报告基因工程猪肾在人体中的临床结局数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with ESKD who would benefit from a kidney transplant face a critical and continuing shortage of kidneys from deceased human donors. As a result, such patients wait a median of 3.9 years to receive a donor kidney, by which time approximately 35% of transplant candidates have died while waiting or have been removed from the waiting list. Those of blood group B or O may experience a significantly longer waiting period. This problem could be resolved if kidneys from genetically engineered pigs offered an alternative with an acceptable clinical outcome. Attempts to accomplish this have followed two major paths: deletion of pig xenoantigens, as well as insertion of "protective" human transgenes to counter the human immune response. Pigs with up to nine genetic manipulations are now available. In nonhuman primates, administering novel agents that block the CD40/CD154 costimulation pathway, such as an anti-CD40 mAb, suppresses the adaptive immune response, leading to pig kidney graft survival of many months without features of rejection (experiments were terminated for infectious complications). In the absence of innate and adaptive immune responses, the transplanted pig kidneys have generally displayed excellent function. A clinical trial is anticipated within 2 years. We suggest that it would be ethical to offer a pig kidney transplant to selected patients who have a life expectancy shorter than the time it would take for them to obtain a kidney from a deceased human donor. In the future, the pigs will also be genetically engineered to control the adaptive immune response, thus enabling exogenous immunosuppressive therapy to be significantly reduced or eliminated.
引用
- Cooper DKC, Hara H, Iwase H, et al. Clinical Pig Kidney Xenotransplantation: How Close Are We? J Am Soc Nephrol. 2019. PMID: 31792154. doi:10.1681/ASN.2019070651
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。